Table 5. Univariate statistical analysis... | American Society of Hematology

Table 5.

Univariate statistical analysis of prognostic factors for patients with cHD treated with ABVD or equivalent regimens

Factor	No. of patients	% 5-y FFS	P^5-150
Age, y	997		.005
45 or older		73
Younger than 45		82
Sex	997		.5
Male		80
Female		81
Stage	997		<.0001
I-III		85
IV		63
B symptoms	997		<.0001
Present		73
Absent		86
Serum albumin level	821		<.0001
Low^5-151		67
Normal		83
Anemia	983		<.0001
Present		76
Absent		86
Leukocytosis^5-152	980		.0006
Present		70
Absent		82
Lymphocytopenia^5-152	840		.02
Present		71
Absent		80
Serum β₂-microglobulin level	486		.0008
High^5-151		73
Normal		85
Serum LDH level	731		.004
High^5-151		76
Normal		84
Bone marrow involvement	996		<.0001
Present		62
Absent		82
Mediastinal mass ratio	436		.9
At least 0.45		80
Lower than 0.45		80
Inguinal or iliac nodes	987		<.0001
Involved		70
Uninvolved		84
BCL-2	412		.001
Positive		74
Negative		88

Factor	No. of patients	% 5-y FFS	P^5-150
Age, y	997		.005
45 or older		73
Younger than 45		82
Sex	997		.5
Male		80
Female		81
Stage	997		<.0001
I-III		85
IV		63
B symptoms	997		<.0001
Present		73
Absent		86
Serum albumin level	821		<.0001
Low^5-151		67
Normal		83
Anemia	983		<.0001
Present		76
Absent		86
Leukocytosis^5-152	980		.0006
Present		70
Absent		82
Lymphocytopenia^5-152	840		.02
Present		71
Absent		80
Serum β₂-microglobulin level	486		.0008
High^5-151		73
Normal		85
Serum LDH level	731		.004
High^5-151		76
Normal		84
Bone marrow involvement	996		<.0001
Present		62
Absent		82
Mediastinal mass ratio	436		.9
At least 0.45		80
Lower than 0.45		80
Inguinal or iliac nodes	987		<.0001
Involved		70
Uninvolved		84
BCL-2	412		.001
Positive		74
Negative		88

By log-rank test.

As defined in “Patients and methods.”

As defined by IPS.5